Judy H. Cho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Judy H. Cho has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Richard H. Duerr
University of Pittsburgh, Pittsburgh, PA, USA
18 shared publications Kyle Gettler
Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai
17 shared publications- Dermot PB McGovern
F. Widjaja Inflammatory Bowel Disease Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA
16 shared publications - Steven R. Brant
Johns Hopkins University
16 shared publications - Jean-Frederic Colombel
The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA
15 shared publications - John David Rioux
Montreal Heart Institute
14 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 15
GM-CSF regulates conserved ILC-like transcriptional states and myeloid cell signaling during ulceration in Crohn’s disease
Macrophage (M-), granulocyte (G-), and granulocyte–macrophage (GM-) colony-stimulating factors (CSFs) regulate myeloid cell function, yet their relative roles during inflammation remain poorly defined. To uncover how CSFs shape spatial immune niches in Crohn’s disease, we performed Xenium single-cell spatial transcriptomics on ileal tissues, revealing cell-type–specific expression and source–target interactions for each CSF. GM-CSF, unlike M-CSF or G-CSF, was locally enriched in ulcerated regions where lymphocytes adjacent to macrophage aggregates signaled through STAT5 phosphorylation. To study functional consequences, we developed a csf2rb⁻/⁻ zebrafish model of intestinal injury. Using this model, we found that loss of GM-CSF signaling exacerbated epithelial damage and inflammation, whereas recombinant human GM-CSF limited injury by restraining ILC1 expansion, sustaining ILC3 maintenance, and promoting IL-22 production. Cross-species single-cell analysis revealed conserved ILC gene modules and GM-CSF–dependent transcriptional networks linking lymphoid and myeloid populations. These findings establish GM-CSF as a critical spatial regulator of myeloid– lymphoid crosstalk and intestinal immune homeostasis in Crohn’s disease.
- 21 October 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 15
Open AccessGM-CSF regulates conserved ILC-like transcriptional states and myeloid cell signaling during ulceration in Crohn’s disease
Macrophage (M-), granulocyte (G-), and granulocyte–macrophage (GM-) colony-stimulating factors (CSFs) regulate myeloid cell function, yet their relative roles during inflammation remain poorly defined. To uncover how CSFs shape spatial immune niches in Crohn’s disease, we performed Xenium single-cell spatial transcriptomics on ileal tissues, revealing cell-type–specific expression and source–target interactions for each CSF. GM-CSF, unlike M-CSF or G-CSF, was locally enriched in ulcerated regions where lymphocytes adjacent to macrophage aggregates signaled through STAT5 phosphorylation. To study functional consequences, we developed a csf2rb⁻/⁻ zebrafish model of intestinal injury. Using this model, we found that loss of GM-CSF signaling exacerbated epithelial damage and inflammation, whereas recombinant human GM-CSF limited injury by restraining ILC1 expansion, sustaining ILC3 maintenance, and promoting IL-22 production. Cross-species single-cell analysis revealed conserved ILC gene modules and GM-CSF–dependent transcriptional networks linking lymphoid and myeloid populations. These findings establish GM-CSF as a critical spatial regulator of myeloid– lymphoid crosstalk and intestinal immune homeostasis in Crohn’s disease.
- Open Access
Characterisation of Genetically-Derived Patient Clusters Highlights Genetic Heterogeneity of Inflammatory Bowel Disease
Background and aims: Inflammatory Bowel Disease (IBD) is a complex immune-mediated condition with a strong genetic contribution. Its genetics are highly complex, with inflammation, autoimmunity, and mucosal immunity pathways involved in its pathogenicity. GenePy is a gene-level disease burden metric. The integration of clinical and genetic data and the application of machine learning can aid patient stratification for personalised care. Methods: Lists of consensus IBD pathway genes were curated. GenePy scores were computed from whole exome sequencing data. A K-Means algorithm was optimised using clustering quality and stability metrics on the GenePy scores of genes in each IBD pathway, and the results replicated in three independent IBD cohorts (SPARC IBD, MSCCR, and Southampton IBD). Chi-square tests assessed the association between cluster assignment and phenotypic features, and were multiple test corrected via Benjamini-Hochberg FDR. Results: A strong association was replicated for NOD signalling genes driving IBD subtype, Crohn’s disease behaviour, and IBD surgery across all cohorts, as well as granuloma in Southampton IBD. This was mainly driven by NOD2 . Similar genetic clustering patterns were observed across all cohorts, with additional phenotypic enrichment in clusters driven by NLRP1 (surgery in MSCCR IBD), and nominally significant enrichment for disease behaviour linked to BIRC2 (B2 in Southampton IBD and B2B3 in SPARC IBD). Conclusions: This analysis identified a common genetic architecture across NOD signalling genes across IBD cohorts, replicated a signal for NOD2 as a monogenic disease driver with a strong phenotypic enrichment, and identified other putative genetic drivers of IBD, such as NLRP1 .
Open AccessCharacterisation of Genetically-Derived Patient Clusters Highlights Genetic Heterogeneity of Inflammatory Bowel Disease
Background and aims: Inflammatory Bowel Disease (IBD) is a complex immune-mediated condition with a strong genetic contribution. Its genetics are highly complex, with inflammation, autoimmunity, and mucosal immunity pathways involved in its pathogenicity. GenePy is a gene-level disease burden metric. The integration of clinical and genetic data and the application of machine learning can aid patient stratification for personalised care. Methods: Lists of consensus IBD pathway genes were curated. GenePy scores were computed from whole exome sequencing data. A K-Means algorithm was optimised using clustering quality and stability metrics on the GenePy scores of genes in each IBD pathway, and the results replicated in three independent IBD cohorts (SPARC IBD, MSCCR, and Southampton IBD). Chi-square tests assessed the association between cluster assignment and phenotypic features, and were multiple test corrected via Benjamini-Hochberg FDR. Results: A strong association was replicated for NOD signalling genes driving IBD subtype, Crohn’s disease behaviour, and IBD surgery across all cohorts, as well as granuloma in Southampton IBD. This was mainly driven by NOD2 . Similar genetic clustering patterns were observed across all cohorts, with additional phenotypic enrichment in clusters driven by NLRP1 (surgery in MSCCR IBD), and nominally significant enrichment for disease behaviour linked to BIRC2 (B2 in Southampton IBD and B2B3 in SPARC IBD). Conclusions: This analysis identified a common genetic architecture across NOD signalling genes across IBD cohorts, replicated a signal for NOD2 as a monogenic disease driver with a strong phenotypic enrichment, and identified other putative genetic drivers of IBD, such as NLRP1 .
- Open Access
Resolving inflammatory bowel disease risk variants to genes and cell types
Inflammatory bowel diseases (IBD), principally Crohn’s disease (CD) and ulcerative colitis (UC), are common chronic disorders involving inflammation and often progressive tissue damage. Genome-wide association studies have mapped many risk signals, but the causal variants, effector genes and relevant cellular contexts remain difficult to resolve, limiting mechanistic interpretation and therapeutic translation. Here we performed a multi-ancestry GWAS meta-analysis of 125,992 individuals with IBD and more than 1.2 million controls, identifying 619 independent association signals (374 novel) at 420 IBD regions that account for 77–80% of SNP-based heritability. Fine-mapping resolved 81 high-confidence variants, 41 not previously reported. Although most signals were shared between CD and UC, 39% showed IBD subtype specificity, with UC signals showing stronger enrichment in functional annotations from intestinal epithelial, secretory and enteroendocrine cells, and CD showing stronger genetic correlations with circulating inflammatory biomarkers, including C-reactive protein and glycoprotein acetylation. Latent causal modelling supported a causal effect of decreased high-density lipoprotein on CD risk. By integrating bulk and single-cell eQTL and pQTL resources using colocalisation and Mendelian randomisation, together with coding-variant evidence from exome sequencing, we prioritised 664 candidate effector genes across 341 signals, including 390 newly implicated IBD genes, revealing new biological mechanisms and candidate therapeutic targets supported by human genetics.
Open AccessResolving inflammatory bowel disease risk variants to genes and cell types
Inflammatory bowel diseases (IBD), principally Crohn’s disease (CD) and ulcerative colitis (UC), are common chronic disorders involving inflammation and often progressive tissue damage. Genome-wide association studies have mapped many risk signals, but the causal variants, effector genes and relevant cellular contexts remain difficult to resolve, limiting mechanistic interpretation and therapeutic translation. Here we performed a multi-ancestry GWAS meta-analysis of 125,992 individuals with IBD and more than 1.2 million controls, identifying 619 independent association signals (374 novel) at 420 IBD regions that account for 77–80% of SNP-based heritability. Fine-mapping resolved 81 high-confidence variants, 41 not previously reported. Although most signals were shared between CD and UC, 39% showed IBD subtype specificity, with UC signals showing stronger enrichment in functional annotations from intestinal epithelial, secretory and enteroendocrine cells, and CD showing stronger genetic correlations with circulating inflammatory biomarkers, including C-reactive protein and glycoprotein acetylation. Latent causal modelling supported a causal effect of decreased high-density lipoprotein on CD risk. By integrating bulk and single-cell eQTL and pQTL resources using colocalisation and Mendelian randomisation, together with coding-variant evidence from exome sequencing, we prioritised 664 candidate effector genes across 341 signals, including 390 newly implicated IBD genes, revealing new biological mechanisms and candidate therapeutic targets supported by human genetics.
- Open Access
Exome sequencing directly implicates 68 genes in inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder of the gastrointestinal tract whose genetic basis is only partly resolved because most risk variants identified by genome-wide association studies (GWAS) lie in non-coding regions, limiting direct gene assignment and biological interpretation 1,2 . Here we analysed whole-exome and whole-genome sequencing data from 86,213 IBD cases and 478,363 controls of European ancestry. We identified 68 IBD genes directly implicated by conditionally independent protein-coding associations across the allele frequency spectrum. Many newly implicated IBD genes are supported by orthogonal genomic or pleiotropic evidence, pointing to disease-related pathways and nominating targets with therapeutic relevance. We further identified allelic series and non-additive effects at key loci such as NOD2 and TYK2. These results show that large-scale sequencing can resolve disease genes and pathways that remain ambiguous from non-coding association alone, providing a more direct route from human genetics to biological insight and therapeutic hypotheses.
Open AccessExome sequencing directly implicates 68 genes in inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder of the gastrointestinal tract whose genetic basis is only partly resolved because most risk variants identified by genome-wide association studies (GWAS) lie in non-coding regions, limiting direct gene assignment and biological interpretation 1,2 . Here we analysed whole-exome and whole-genome sequencing data from 86,213 IBD cases and 478,363 controls of European ancestry. We identified 68 IBD genes directly implicated by conditionally independent protein-coding associations across the allele frequency spectrum. Many newly implicated IBD genes are supported by orthogonal genomic or pleiotropic evidence, pointing to disease-related pathways and nominating targets with therapeutic relevance. We further identified allelic series and non-additive effects at key loci such as NOD2 and TYK2. These results show that large-scale sequencing can resolve disease genes and pathways that remain ambiguous from non-coding association alone, providing a more direct route from human genetics to biological insight and therapeutic hypotheses.
- 28 April 2026
- Published by Elsevier in Gastroenterology
- Vol. 171 (2) , 382
Reply
- Open Access
- 27 April 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 15
GM-CSF regulates ILC states and myeloid cell signaling during ulceration in Crohn’s disease
Macrophage (M-), granulocyte (G-), and granulocyte–macrophage (GM-) colony-stimulating factors (CSFs) regulate myeloid cell function, yet their relative roles during inflammation remain poorly defined. To uncover how CSFs shape spatial immune niches in Crohn’s disease, we performed Xenium single-cell spatial transcriptomics on ileal tissues, revealing cell-type–specific expression and source–target interactions for each CSF. GM-CSF, unlike M-CSF or G-CSF, was locally enriched in ulcerated regions where lymphocytes adjacent to macrophage aggregates signaled through STAT5 phosphorylation. To study functional consequences, we developed a csf2rb⁻/⁻ zebrafish model of intestinal injury. Using this model, we found that loss of GM-CSF signaling exacerbated epithelial damage and inflammation, whereas recombinant human GM-CSF limited injury by restraining ILC1 expansion, sustaining ILC3 maintenance, and promoting IL-22 production. Cross-species single-cell analysis revealed conserved ILC gene modules and GM-CSF–dependent transcriptional networks linking lymphoid and myeloid populations. These findings establish GM-CSF as a critical spatial regulator of myeloid-lymphoid crosstalk and intestinal immune homeostasis in Crohn’s disease.
- 27 April 2026
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 15
Open AccessGM-CSF regulates ILC states and myeloid cell signaling during ulceration in Crohn’s disease
Macrophage (M-), granulocyte (G-), and granulocyte–macrophage (GM-) colony-stimulating factors (CSFs) regulate myeloid cell function, yet their relative roles during inflammation remain poorly defined. To uncover how CSFs shape spatial immune niches in Crohn’s disease, we performed Xenium single-cell spatial transcriptomics on ileal tissues, revealing cell-type–specific expression and source–target interactions for each CSF. GM-CSF, unlike M-CSF or G-CSF, was locally enriched in ulcerated regions where lymphocytes adjacent to macrophage aggregates signaled through STAT5 phosphorylation. To study functional consequences, we developed a csf2rb⁻/⁻ zebrafish model of intestinal injury. Using this model, we found that loss of GM-CSF signaling exacerbated epithelial damage and inflammation, whereas recombinant human GM-CSF limited injury by restraining ILC1 expansion, sustaining ILC3 maintenance, and promoting IL-22 production. Cross-species single-cell analysis revealed conserved ILC gene modules and GM-CSF–dependent transcriptional networks linking lymphoid and myeloid populations. These findings establish GM-CSF as a critical spatial regulator of myeloid-lymphoid crosstalk and intestinal immune homeostasis in Crohn’s disease.
- Open Access
GM-CSF regulates ILC states and myeloid cell signaling during ulceration in Crohn’s disease
Macrophage (M-), granulocyte (G-), and granulocyte–macrophage (GM-) colony-stimulating factors (CSFs) regulate myeloid cell function, yet their relative roles during inflammation remain poorly defined. To uncover how CSFs shape spatial immune niches in Crohn’s disease, we performed Xenium single-cell spatial transcriptomics on ileal tissues, revealing cell-type–specific expression and source–target interactions for each CSF. GM-CSF, unlike M-CSF or G-CSF, was locally enriched in ulcerated regions where lymphocytes adjacent to macrophage aggregates signaled through STAT5 phosphorylation. To study functional consequences, we developed a csf2rb−/− zebrafish model of intestinal injury. Using this model, we found that loss of GM-CSF signaling exacerbated epithelial damage and inflammation, whereas recombinant human GM-CSF limited injury by restraining ILC1 expansion, sustaining ILC3 maintenance, and promoting IL-22 production. Cross-species single-cell analysis revealed conserved ILC gene modules and GM-CSF–dependent transcriptional networks linking lymphoid and myeloid populations. These findings establish GM-CSF as a critical spatial regulator of myeloid–lymphoid crosstalk and intestinal immune homeostasis in Crohn’s disease.
Open AccessGM-CSF regulates ILC states and myeloid cell signaling during ulceration in Crohn’s disease
Macrophage (M-), granulocyte (G-), and granulocyte–macrophage (GM-) colony-stimulating factors (CSFs) regulate myeloid cell function, yet their relative roles during inflammation remain poorly defined. To uncover how CSFs shape spatial immune niches in Crohn’s disease, we performed Xenium single-cell spatial transcriptomics on ileal tissues, revealing cell-type–specific expression and source–target interactions for each CSF. GM-CSF, unlike M-CSF or G-CSF, was locally enriched in ulcerated regions where lymphocytes adjacent to macrophage aggregates signaled through STAT5 phosphorylation. To study functional consequences, we developed a csf2rb−/− zebrafish model of intestinal injury. Using this model, we found that loss of GM-CSF signaling exacerbated epithelial damage and inflammation, whereas recombinant human GM-CSF limited injury by restraining ILC1 expansion, sustaining ILC3 maintenance, and promoting IL-22 production. Cross-species single-cell analysis revealed conserved ILC gene modules and GM-CSF–dependent transcriptional networks linking lymphoid and myeloid populations. These findings establish GM-CSF as a critical spatial regulator of myeloid–lymphoid crosstalk and intestinal immune homeostasis in Crohn’s disease.
- Open Access
- 14 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Automating clinical phenotyping using natural language processing
Background: Real-world studies based on electronic health records often require manual chart review to derive patients’ clinical phenotypes, a labor-intensive task with limited scalability. Here, we developed and compared computable phenotyping based on rules using the spaCy framework and a Large Language Model (LLM), GPT-4, for sub-phenotyping of patients with Crohn’s disease, considering age at diagnosis and disease behavior. Methods: For our rule-based approach, we leveraged the spaCy framework and for the LLM-based approach, we used the GPT-4 model. The underlying data included 49,572 clinical notes and 2204 radiology reports from 584 Crohn’s disease patients. A test set of 280 clinical texts was labeled at sentence-level, in addition to patient-level ground truth data. The algorithms were evaluated based on their recall, precision, specificity values, and F1 scores. Results: Overall, we observe similar or better performance using GPT-4 compared to the rules. On a note-level, the F1 score is at least 0.90 for disease behavior and 0.82 for age at diagnosis, and on patient level at least 0.66 for disease behavior and 0.71 for age at diagnosis. Conclusions: To our knowledge, this is the first study to explore computable phenotyping algorithms based on clinical narrative text for these complex tasks, where prior inter-annotator agreements ranged from 0.54 to 0.98. There is no statistical evidence for a difference to the performance of human experts on this task. Our findings underline the potential of LLMs for computable phenotyping and may support large-scale cohort analyses from electronic health records and streamline chart review processes in the future.
- 14 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessAutomating clinical phenotyping using natural language processing
Background: Real-world studies based on electronic health records often require manual chart review to derive patients’ clinical phenotypes, a labor-intensive task with limited scalability. Here, we developed and compared computable phenotyping based on rules using the spaCy framework and a Large Language Model (LLM), GPT-4, for sub-phenotyping of patients with Crohn’s disease, considering age at diagnosis and disease behavior. Methods: For our rule-based approach, we leveraged the spaCy framework and for the LLM-based approach, we used the GPT-4 model. The underlying data included 49,572 clinical notes and 2204 radiology reports from 584 Crohn’s disease patients. A test set of 280 clinical texts was labeled at sentence-level, in addition to patient-level ground truth data. The algorithms were evaluated based on their recall, precision, specificity values, and F1 scores. Results: Overall, we observe similar or better performance using GPT-4 compared to the rules. On a note-level, the F1 score is at least 0.90 for disease behavior and 0.82 for age at diagnosis, and on patient level at least 0.66 for disease behavior and 0.71 for age at diagnosis. Conclusions: To our knowledge, this is the first study to explore computable phenotyping algorithms based on clinical narrative text for these complex tasks, where prior inter-annotator agreements ranged from 0.54 to 0.98. There is no statistical evidence for a difference to the performance of human experts on this task. Our findings underline the potential of LLMs for computable phenotyping and may support large-scale cohort analyses from electronic health records and streamline chart review processes in the future.
- Open Access
- 18 November 2025
- Published by Elsevier in Gastroenterology
- Vol. 170 (3) , 511-522
Postoperative Ileum Transcriptomics Implicate Sex-Biased Mechanisms in Crohn’s Disease Recurrence
- 18 November 2025
- Published by Elsevier in Gastroenterology
- Vol. 170 (3) , 511-522
Open AccessPostoperative Ileum Transcriptomics Implicate Sex-Biased Mechanisms in Crohn’s Disease Recurrence
- 28 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6763) , eadm7066
Machine learning–based penetrance of genetic variants
Accurate variant penetrance estimation is crucial for precision medicine. We constructed machine learning (ML) models for 10 diseases using 1,347,298 participants with electronic health records, then applied them to an independent cohort with linked exome data. Resulting probabilities were used to evaluate ML penetrance of 1648 rare variants in 31 autosomal dominant disease-predisposition genes. ML penetrance was variable across variant classes, but highest for pathogenic and loss-of-function variants, and was associated with clinical outcomes and functional data. Compared with conventional case-versus-control approaches, ML penetrance provided refined quantitative estimates and aided the interpretation of variants of uncertain significance and loss-of-function variants by delineating clinical trajectories over time. By leveraging ML and deep phenotyping, we present a scalable approach to accurately quantify disease risk of variants.
- 28 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6763) , eadm7066
Machine learning–based penetrance of genetic variants
Accurate variant penetrance estimation is crucial for precision medicine. We constructed machine learning (ML) models for 10 diseases using 1,347,298 participants with electronic health records, then applied them to an independent cohort with linked exome data. Resulting probabilities were used to evaluate ML penetrance of 1648 rare variants in 31 autosomal dominant disease-predisposition genes. ML penetrance was variable across variant classes, but highest for pathogenic and loss-of-function variants, and was associated with clinical outcomes and functional data. Compared with conventional case-versus-control approaches, ML penetrance provided refined quantitative estimates and aided the interpretation of variants of uncertain significance and loss-of-function variants by delineating clinical trajectories over time. By leveraging ML and deep phenotyping, we present a scalable approach to accurately quantify disease risk of variants.